![The CD70-CD27 axis in oncology: the new kids on the block | Journal of Experimental & Clinical Cancer Research | Full Text The CD70-CD27 axis in oncology: the new kids on the block | Journal of Experimental & Clinical Cancer Research | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13046-021-02215-y/MediaObjects/13046_2021_2215_Fig2_HTML.png)
The CD70-CD27 axis in oncology: the new kids on the block | Journal of Experimental & Clinical Cancer Research | Full Text
![Safety and activity of varlilumab, a novel and first-in-class agonist anti- CD27 antibody, for hematologic malignancies - ScienceDirect Safety and activity of varlilumab, a novel and first-in-class agonist anti- CD27 antibody, for hematologic malignancies - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2473952920313239-gr1.jpg)
Safety and activity of varlilumab, a novel and first-in-class agonist anti- CD27 antibody, for hematologic malignancies - ScienceDirect
![The CD70-CD27 axis in oncology: the new kids on the block | Journal of Experimental & Clinical Cancer Research | Full Text The CD70-CD27 axis in oncology: the new kids on the block | Journal of Experimental & Clinical Cancer Research | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13046-021-02215-y/MediaObjects/13046_2021_2215_Fig3_HTML.png)
The CD70-CD27 axis in oncology: the new kids on the block | Journal of Experimental & Clinical Cancer Research | Full Text
![Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering | Communications Biology Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering | Communications Biology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs42003-022-03182-6/MediaObjects/42003_2022_3182_Fig1_HTML.png)
Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering | Communications Biology
![Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential | Immunotherapy Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential | Immunotherapy](https://www.futuremedicine.com/cms/10.2217/imt.15.32/asset/images/medium/figure1.gif)
Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential | Immunotherapy
![The CD70-CD27 axis in oncology: the new kids on the block | Journal of Experimental & Clinical Cancer Research | Full Text The CD70-CD27 axis in oncology: the new kids on the block | Journal of Experimental & Clinical Cancer Research | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13046-021-02215-y/MediaObjects/13046_2021_2215_Fig1_HTML.png)
The CD70-CD27 axis in oncology: the new kids on the block | Journal of Experimental & Clinical Cancer Research | Full Text
![Frontiers | Targeting the CD27-CD70 Pathway to Improve Outcomes in Both Checkpoint Immunotherapy and Allogeneic Hematopoietic Cell Transplantation Frontiers | Targeting the CD27-CD70 Pathway to Improve Outcomes in Both Checkpoint Immunotherapy and Allogeneic Hematopoietic Cell Transplantation](https://www.frontiersin.org/files/Articles/715909/fimmu-12-715909-HTML-r1/image_m/fimmu-12-715909-g001.jpg)
Frontiers | Targeting the CD27-CD70 Pathway to Improve Outcomes in Both Checkpoint Immunotherapy and Allogeneic Hematopoietic Cell Transplantation
![The Interplay between CD27dull and CD27bright B Cells Ensures the Flexibility, Stability, and Resilience of Human B Cell Memory - ScienceDirect The Interplay between CD27dull and CD27bright B Cells Ensures the Flexibility, Stability, and Resilience of Human B Cell Memory - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2211124720301765-fx1.jpg)